#China #Xi'an #Immunoassay #KHB #Polaris V150

KHB Unveils the Polaris V150 at MEDICA 2025

At the prestigious MEDICA 2025 exhibition, Shanghai Kehua Bio-engineering Co., Ltd. (KHB), a leading global provider of in vitro diagnostic (IVD) solutions, introduced their latest innovation, the compact Polaris V150 automated immunoassay analyzer. This cutting-edge device highlights KHB's ongoing commitment to pioneering advancements in laboratory automation.

Overview of the Polaris V150

Designed specifically for small to medium-sized laboratories, as well as for STAT testing in large hospitals and external labs, the Polaris V150 brings remarkable efficiency and precision, all within a compact desktop footprint. With an operational space requirement of just 0.36 square meters, it provides robust immunological testing capabilities without the need for external devices, featuring a built-in touch screen for user convenience.

Compact Design and High Performance

Despite its small size, the Polaris V150 can execute up to 150 tests per hour, enabling labs to enhance their operational efficiency in tight spaces. This analyzer allows for continuous loading of samples, reagents, and reaction cups. The STAT function ensures urgent specimens are processed with priority, facilitating swift medical decision-making. The system accommodates 40 sample positions, supports both serum and plasma, and features automatic dilution along with comprehensive detection of liquid levels, clot presence, and collisions, significantly boosting reliability.

High Accuracy with ALP-AMPPD Technology

Equipped with a high-efficiency ALP-AMPPD chemiluminescent system, the Polaris V150 consistently delivers high accuracy and precision across all tests (CV < 3%). This analyzer utilizes a comprehensive range of reagents, including calibration standards with QR code information and standard curves, ensuring standardized operation and simplified reagent management. Additionally, the Polaris V150 supports an ever-expanding list of tests, covering over 60 assays across 10 panels for major diseases, addressing a wide array of routine diagnostic needs. The tests encompass thyroid function markers, sex hormones, cancer markers, infectious diseases, cardiac markers, inflammatory conditions, glycometabolism, anemia, bone metabolism, and much more.

Enhanced User Experience and Intelligent Systems

Beyond analytic performance, the Polaris V150 incorporates an intelligent system design that enhances a laboratory's usability. The platform enables real-time monitoring of reagent and consumable status, granting laboratories full control over their operational readiness. Its clear, intuitive user interface and built-in touch screen facilitate navigation and streamline operation, reducing training requirements and improving the overall user experience.

Optimal Reagent Stability and Smart Maintenance

To maintain peak performance, the analyzer features 24/7 cooling (2-8°C) for up to 12 reagent positions, ensuring optimal stability. Remote monitoring capabilities and automated maintenance functions minimize downtimes and ease service processes, allowing labs to achieve high continuity in operations.

A Highlight at MEDICA 2025

The Polaris V150 has emerged as a standout at the MEDICA 2025 exhibition, drawing considerable attention from global partners in search of compact yet efficient solutions for immunological testing. Attendees engaged with KHB's team of experts through live demonstrations and technical consultations, gaining firsthand insight into the device's capabilities in both routine and emergency laboratory settings.

"The interest we garnered at MEDICA showcases the strong demand for compact, high-quality chemiluminescent systems like the Polaris V150," stated KHB’s product manager. "We are excited to share this innovation with our international partners, supporting laboratories around the world with efficient immunoassay solutions."

About KHB

Shanghai Kehua Bio-engineering Co., Ltd. (KHB), listed under stock code 002022.SZ, specializes in in vitro diagnostics, providing a comprehensive range of medical diagnostic products focused on immunological, biochemical, molecular diagnostics, and point-of-care testing (POCT). Established in 1981, KHB has developed into a high-tech enterprise integrating R&D, manufacturing, and marketing. The company went public on the Shenzhen Stock Exchange in 2004. For more information, visit the KHB official website and follow their profiles on LinkedIn, Facebook, and Twitter.